688553.SH
Sichuan Huiyu Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 12.04
+1.01%Sep 17, 2026, 09:16 UTC
Huiyu Pharmaceutical shareholder Huang Qianyi plans to passively reduce up to 2.46% of the company's shares (no more than 15.3923 million shares) via centralized bidding and block trades between October 19, 2026 and January 16, 2027 due to judicial enforcement.
Sep 14, 2026, 15:28 UTC
Huiyu Pharmaceutical said it will continue to expand the scope of AI tool applications based on actual R&D scenarios.
Source:Aug 19, 2026, 09:07 UTC
Huiyu Pharmaceutical's wholly-owned subsidiary Huiyu Haiyue received approval from China's National Medical Products Administration to conduct clinical trials for its investigational drug HY07121 (subcutaneous injection) for treating advanced solid tumors.
Aug 10, 2026, 09:04 UTC
Huiyu Pharmaceutical's subsidiary Seacross (Europe) Pharma Ltd. received marketing approvals from German, Dutch, and Spanish regulators for its products parecoxib sodium for injection and zoledronic acid injection.
Source: